Albany Molecular Research VP Lori M. Henderson Unloads 2,500 Shares (AMRI)
Albany Molecular Research (NASDAQ:AMRI) VP Lori M. Henderson unloaded 2,500 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $15.73, for a total value of $39,325.00. Following the transaction, the vice president now directly owns 53,997 shares of the company’s stock, valued at approximately $849,373. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Albany Molecular Research (NASDAQ:AMRI) traded down 0.87% during mid-day trading on Thursday, hitting $15.92. 495,041 shares of the company’s stock traded hands. Albany Molecular Research has a one year low of $9.71 and a one year high of $20.55. The stock has a 50-day moving average of $17.2 and a 200-day moving average of $13.47. The company has a market cap of $494.9 million and a P/E ratio of 40.15.
Albany Molecular Research (NASDAQ:AMRI) last released its earnings data on Wednesday, February 12th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.05. Analysts expect that Albany Molecular Research will post $0.79 EPS for the current fiscal year.
AMRI has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Albany Molecular Research from an “outperform” rating to a “neutral” rating in a research note on Tuesday, April 15th. They now have a $17.80 price target on the stock. Finally, analysts at Morgan Stanley initiated coverage on shares of Albany Molecular Research in a research note on Wednesday, April 9th. They set an “overweight” rating and a $19.00 price target on the stock.
Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.